RE:RE:6$ Target purely based on operations, what's your taget@Possibleidiot01
$600 million is roughly 6$ per share. This price doesn't include any premium that a strategic acquirer would be ready to pay to takeover Opsens.
'' According to Sarugaser, the FIH study starting in the third quarter of 2021 begins a pivotal nine-month growth period for the company, with the readout and data completion expected in the fourth quarter, and the company’s rNPV rising to a projected $355 million. From there, the 510(k) submission to the U.S. FDA is expected in the first quarter of 2022, accompanied by the rNPV increasing to a projected $530 million, paving the way for FDA clearance and the beginning of marketing and promotion efforts in Canada and the United States early in the second half of 2022, bringing the company’s rNPV to a projected $600 million.''